Chemogenomic analysis identifies macbecin ii as a compound specific for smad4-negative colon cancer cells: Research article

Chemical Biology and Drug Design

Volumn 75, Issue 4, 2010, Pages 360-368

  Kaiser, Christine ^a,b   Meurice, Nathalie ^a   Gonzales, Irma M ^a   Arora, Shilpi ^a   Beaudry, Christian ^a   Bisanz, Kristen M ^a   Robeson, Alexander C ^a   Petit, Joachim ^a   Azorsa, David O ^a  

^a TRANSLATIONAL GENOMICS RESEARCH INSTITUTE   (United States)

^b ARIZONA STATE UNIVERSITY   (United States)

Author keywords

Cheminformatics; Colon cancer; Macbecin II; NCI 60; SMAD4

Indexed keywords

ANTINEOPLASTIC ANTIBIOTIC; MACBECIN II; SMAD4 PROTEIN; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL GROWTH; CELL VIABILITY; CHEMINFORMATICS; COLON CANCER; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG IDENTIFICATION; DRUG POTENCY; DRUG STRUCTURE; GENE SILENCING; GROWTH INHIBITION; HUMAN; HUMAN CELL; INFORMATION PROCESSING; PHARMACOGENOMICS; PRIORITY JOURNAL; PROTEIN EXPRESSION; WILD TYPE;

ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; BENZOQUINONES; CELL LINE, TUMOR; COLONIC NEOPLASMS; DRUG DISCOVERY; GENE SILENCING; GENOMICS; HCT116 CELLS; HT29 CELLS; HUMANS; LACTAMS, MACROCYCLIC; RNA INTERFERENCE; RNA, SMALL INTERFERING; SMAD4 PROTEIN;

EID: 77449129655     PISSN: 17470277     EISSN: 17470285     Source Type: Journal    
DOI: 10.1111/j.1747-0285.2010.00949.x     Document Type: Article

References (35)

1. Hahn S.A., Schutte M., Hoque A.T., Moskaluk C.A., da Costa L.T., Rozenblum E., Weinstein C.L., Fischer A., Yeo C.J., Hruban R.H., Kern S.E. (1996) DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science 271 : 350 353.
2. Schutte M., Hruban R.H., Hedrick L., Cho K.R., Nadasdy G.M., Weinstein C.L., Bova G.S., Isaacs W.B., Cairns P., Nawroz H., Sidransky D., Casero R.A. Jr., Meltzer P.S., Hahn S.A., Kern S.A. (1996) DPC4 gene in various tumor types. Cancer Res 56 : 2527 2530.
3. Gordon K.J., Blobe G.C. (2008) Role of transforming growth factor-beta superfamily signaling pathways in human disease. Biochim Biophys Acta 1782 : 197 228.
4. Massague J., Wotton D. (2000) Transcriptional control by the TGF-beta/Smad signaling system. EMBO J 19 : 1745 1754.
5. Massague J., Seoane J., Wotton D. (2005) Smad transcription factors. Genes Dev 19 : 2783 2810.
6. Massague J., Blain S.W., Lo R.S. (2000) TGFbeta signaling in growth control, cancer, and heritable disorders. Cell 103 : 295 309.
7. Blobe G.C., Schiemann W.P., Lodish H.F. (2000) Role of transforming growth factor beta in human disease. N Eng J Med 342 : 1350 1358.
8. Wang H., Stephens B., Von Hoff D.D., Han H. (2009) Identification and characterization of a novel anticancer agent with selectivity against deleted in pancreatic cancer locus 4 (DPC4)-deficient pancreatic and colon cancer cells. Pancreas 38 : 551 557.
9. Parkin D.M., Bray F., Ferlay J., Pisani P. (2005) Global cancer statistics, 2002. CA Cancer J Clin 55 : 74 108.
10. Shoemaker R.H. (2006) The NCI60 human tumour cell line anticancer drug screen. Nat Rev 6 : 813 823.
11. Ikediobi O.N., Davies H., Bignell G., Edkins S., Stevens C., O'Meara S., Santarius T. (2006) Mutation analysis of 24 known cancer genes in the NCI-60 cell line set. Mol Cancer Ther 5 : 2606 2612.
12. Scherf U., Ross D.T., Waltham M., Smith L.H., Lee J.K., Tanabe L., Kohn K.W. (2000) A gene expression database for the molecular pharmacology of cancer. Nat Genet 24 : 236 244. (Pubitemid 30132190)
13. Roschke A.V., Tonon G., Gehlhaus K.S., McTyre N., Bussey K.J., Lababidi S., Scudiero D.A., Weinstein J.N., Kirsch I.R. (2003) Karyotypic complexity of the NCI-60 drug-screening panel. Cancer Res 63 : 8634 8647.
14. Wang H., Klinginsmith J., Dong X., Lee A.C., Guha R., Wu Y., Crippen G.M., Wild D.J. (2007) Chemical data mining of the NCI human tumor cell line database. J Chem Inf Model 47 : 2063 2076.
15. Shi L.M., Fan Y., Myers T.G., O'Connor P.M., Paull K.D., Friend S.H., Weinstein J.N. (1998) Mining the NCI anticancer drug discovery databases: genetic function approximation for the QSAR study of anticancer ellipticine analogues. J Chem Inf Comput Sci 38 : 189 199.
16. Shi L.M., Fan Y., Lee J.K., Waltham M., Andrews D.T., Scherf U., Paull K.D., Weinstein J.N. (2000) Mining and visualizing large anticancer drug discovery databases. J Chem Inf Comput Sci 40 : 367 379.
17. Glover C.J., Rabow A.A., Isgor Y.G., Shoemaker R.H., Covell D.G. (2007) Data mining of NCI's anticancer screening database reveals mitochondrial complex I inhibitors cytotoxic to leukemia cell lines. Biochem Pharmacol 73 : 331 340.
18. NCI Drug synthesis and Chemistry Branch, Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute.
19. Ben-Dor A., Doron L., Tsalenko A., Reimers M., Baumbusch L., Barrett M., Weinstein J., Børresen-Dale A.L., Yakhini Z. (2007) Framework for identifying common aberrations in DNA copy number data. Framework for Identifying Common Aberrations in DNA Copy Number Data. Lect Notes Comput Sci 4453 : 122 136.
20. Agilent G4175AA CGH (2006) Analytics 3.4 User Guide, Agilent Technologies. 193 211.
21. Sheridan R.P. (2000) The centroid approximation for mixtures: calculating similarity and deriving structure - activity relationships. J Chem Inf Comput Sci 40 : 1456 1469.
22. Sheridan R.P.M.M., Underwood D.J., Kearsley S.K. (1996) Chemical Similarity Using Geometric Atom Pair Descriptors. J Chem Inf Comput Sci 36 : 128 136.
23. Brown R.D., Martin Y.C. (1996) Use of Structure-Activity Data to Compare Structure-Based Clustering Methods and Descriptors for Use in Compound Selection. J Chem Inf Comput Sci 36 : 572 584.
24. Oprea T.I. (2000) Property distribution of drug-related chemical databases. J Comput Aided Mol Des 14 : 251 264.
25. Azorsa D.O., Gonzales I.M., Basu G.D., Choudhary A., Arora S., Bisanz K.M., Kiefer J.A., Henderson M.C., Trent J.M., Von Hoff D.D., Mousses S. (2009) Synthetic lethal RNAi screening identifies sensitizing targets for gemcitabine therapy in pancreatic cancer. J Transl Med 7 : 43.
26. Arora S., Wang Y., Jia Z., Vardar-Sengul S., Munawar A., Doctor K.S., Mirrer M., McClelland M., Adamson E., Mercola D. (2008) Egr1 regulates the coordinated expression of numerous EGF receptor target genes as identified by ChIP-on-chip. Genome Biol 9 : R166.
27. Beyersmann D., Hartwig A. (2008) Carcinogenic metal compounds: recent insight into molecular and cellular mechanisms. Arch Toxicol 82 : 493 512.
28. Stebbins C.E., Russo A.A., Schneider C., Rosen N., Hartl F.U., Pavletich N.P. (1997) Crystal structure of an Hsp90-geldanamycin complex: targeting of a protein chaperone by an antitumor agent. Cell 89 : 239 250.
29. Wang H., Han H., Von Hoff D.D. (2006) Identification of an agent selectively targeting DPC4 (deleted in pancreatic cancer locus 4)-deficient pancreatic cancer cells. Cancer Res 66 : 9722 9730.
30. Dixit V., Juliano R.L. (2008) Selective killing of Smad4-negative tumor cells via a designed repressor strategy. Mol Pharmacol 74 : 289 297.
31. Tanida S., Hasegawa T., Higashide E. (1980) Macbecins I and II, new antitumor antibiotics. I. Producing organism, fermentation and antimicrobial activities. J Antibiot 33 : 199 204. (Pubitemid 10066236)
32. McClellan A.J., Xia Y., Deutschbauer A.M., Davis R.W., Gerstein M., Frydman J. (2007) Diverse cellular functions of the Hsp90 molecular chaperone uncovered using systems approaches. Cell 131 : 121 135.
33. Bohen S.P. (1998) Genetic and biochemical analysis of p23 and ansamycin antibiotics in the function of Hsp90-dependent signaling proteins. Mol Cell Biol 18 : 3330 3339.
34. Neckers L., Kern A., Tsutsumi S. (2007) Hsp90 inhibitors disrupt mitochondrial homeostasis in cancer cells. Chem Biol 14 : 1204 1206.
35. Tsutsumi S., Beebe K., Neckers L. (2009) Impact of heat-shock protein 90 on cancer metastasis. Future Oncol 5 : 679 688.